Stuart Drugs in Psychiatric Practice

1. Auflage 2013
ISBN: 978-1-4831-9193-5
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 454 Seiten, Web PDF

Drugs in Psychiatric Practice present a comprehensive examination of the drug treatment in psychiatry. It discusses certain ways in which drugs behaved. It addresses the advances in pharmacology and the basis of prescription. Some of the topics covered in the book are the classification of psychotropic drugs; basic principles of pharmacokinetics and drug metabolism; anti-schizophrenic drugs; evaluation of psychotropic drugs; unconventional chemotherapy; anti-parkinsonian and anti-dyskinetic drugs; introduction of amitriptyline; and tricyclic antidepressants. The role of tricyclic drugs in the treatment of enuresis and the drug treatment of organic brain syndrome are fully covered. An in-depth account of the monoamine oxidase inhibitors and amine precursors are provided. The tolerance and pharmacological dependence on alcohol are completely presented. A chapter is devoted to the factors involve in ethanol metabolism. Another section focuses on the unwanted effects of psychotropic drugs. The book can provide useful information to doctors, pharmacists, psychologists, students, and researchers.

Dr. Sam Stuart is a physiotherapist and a research Fellow within the Balance Disorders Laboratory, OHSU. His work focuses on vision, cognition and gait in neurological disorders, examining how technology-based interventions influence these factors. He has published extensively in world leading clinical and engineering journals focusing on a broad range of activities such as real-world data analytics, algorithm development for wearable technology and provided expert opinion on technology for concussion assessment for robust player management. He is currently a guest editor for special issues (sports medicine and transcranial direct current stimulation for motor rehabilitation) within Physiological Measurement and Journal of NeuroEngineering and Rehabilitation, respectively.

Autoren/Hrsg.

Stuart, Sam

Inhaltsverzeichnis

1;Front Cover;1
2;Drugs in Psychiatric Practice;4
3;Copyright Page;5
4;Table of Contents;10
5;Preface;6
6;Contributors;8
7;Introduction;14
8;References;15
9;Chapter 1. Classification of psychotropic drugs;16
9.1;What is a psychotropic drug?;16
9.2;Types of classification;16
9.3;Classification of drugs used in this book;22
9.4;References;23
10;Chapter 2. Pharmacokinetics and drug metabolismbasic principles;24
10.1;Definitions and basic principles in pharmacokinetics;24
10.2;Multiple administration;30
10.3;Absorption;30
10.4;Protein binding and distribution;33
10.5;Metabolism;35
10.6;Excretion;38
10.7;Pharmacokinetics and pharmacological effect;39
10.8;Conclusions;42
10.9;References;43
11;Chapter 3. Evaluation of psychotropic drugs;44
11.1;Animal studies;44
11.2;Experimental studies in volunteers;46
11.3;Experimental studies in patients;48
11.4;Early clinical trials;48
11.5;Marketing;51
11.6;Early and late clinical evaluation;52
11.7;References;53
12;Chapter 4. Antischizophrenic drugs;55
12.1;Introduction;55
12.2;Nomenclature;59
12.3;Unconventional chemotherapy;60
12.4;Pharmacology;61
12.5;Non-DA-related pharmacology;65
12.6;Pharmacokinetics;68
12.7;Clinical efficacy;74
12.8;Unwanted effects;81
12.9;References;89
13;Chapter 5. Antiparkinsonian and antidyskinetic drugs;95
13.1;Introduction;95
13.2;Pathophysiology of neuroleptic-induced movement disorders;96
13.3;Drug treatment of neuroleptic-induced movement disorders;102
13.4;References;129
14;Chapter 6. Antianxiety drugs;139
14.1;Generalized central anxiolytics (sedative drugs);139
14.2;Specific central anxiolytics (ataractic drugs);147
14.3;Combined preparations including antianxiety drugs;175
14.4;Peripheral anxiolytics;176
14.5;Comparison of antianxiety drugs;182
14.6;References;182
15;Chapter 7. Tricyclic antidepressants;190
15.1;Introduction;190
15.2;Pharmacology;192
15.3;Pharmacokinetics;193
15.4;Clinical use;197
15.5;Introduction of amitriptyline;199
15.6;Other tricyclic antidepressant drugs;200
15.7;Comparisons between tricyclic drugs and other antidepressive treatments;211
15.8;Tricyclic drugs in the treatment of enuresis;215
15.9;General topics concerning the tricyclic drugs;216
15.10;Unwanted effects;219
15.11;References;223
16;Chapter 8. New generation of antidepressants;232
16.1;Tricyclic antidepressants;233
16.2;MAO inhibitors;234
16.3;Maprotiline (Ludiomil);235
16.4;Mianserin (Bolvidon, Norval);237
16.5;Flupenthixol (Fluanxol);243
16.6;Nomifensine (Merital);245
16.7;Trazodone (Molipaxin);248
16.8;Zimelidine;251
16.9;Comments;252
16.10;Summary;252
16.11;References;253
17;Chapter 9. Monoamine oxidase inhibitors and amine precursors;262
17.1;Pharmacology;263
17.2;Pharmacokinetics;265
17.3;Dosage and clinical response;271
17.4;Unwanted effects;274
17.5;Individual monoamine oxidase inhibitors;280
17.6;Main clinical indications for MAOIs;283
17.7;Amine precursors;284
17.8;Summary;287
17.9;References;287
18;Chapter 10. Lithium carbonate;293
18.1;Introduction and historical aspects;293
18.2;Pharmacology;294
18.3;Pharmacokinetics;295
18.4;Determination of lithium concentration;299
18.5;Lithium preparations;300
18.6;Clinical use;302
18.7;Treatment of depression with lithium;307
18.8;Lithium and schizoaffective disorders;308
18.9;Lithium and other conditions;309
18.10;Unwanted effects;310
18.11;Drug interactions;312
18.12;Unwanted and toxic effects of lithium;314
18.13;Acknowledgements;318
18.14;References;318
19;Chapter 11. Psychostimulants;326
19.1;Introduction;326
19.2;Pharmacology;326
19.3;Pharmacokinetics;327
19.4;Clinical efficacy;328
19.5;Methylphenidate;329
19.6;Other psychostimulants;330
19.7;Drug interactions;332
19.8;References;332
20;Chapter 12. Drugs of dependence;334
20.1;Controlled drugs;336
20.2;Opiate drugs;337
20.3;Tobacco smoking and nicotine dependence;349
20.4;Amphetamines;351
20.5;Solvent abuse;354
20.6;Minor analgesic abuse;355
20.7;Non-barbiturate sedatives;356
20.8;Barbiturates;357
20.9;Cannabis;358
20.10;Cocaine;360
20.11;References;360
21;Chapter 13. Alcohol;365
21.1;Historical background;365
21.2;Ethanol metabolism;365
21.3;Ethanol oxidation;366
21.4;Problem drinking;368
21.5;Tolerance and pharmacological dependence;368
21.6;Alcohol and women;370
21.7;Ethanol and the neuronal membrane;370
21.8;Clinical use of ethanol;371
21.9;Drug treatment for problem drinking;372
21.10;References;377
22;Chapter 14. Drugs in child psychiatry;380
22.1;Pharmacokinetics;381
22.2;Pharmacodynamics;381
22.3;Tricyclic antidepressants;383
22.4;Monoamine oxidase inhibitors;384
22.5;Lithium carbonate;384
22.6;Summary of clinical use;386
22.7;Unwanted effects of psychotropic drugs in children;387
22.8;References;390
23;Chapter 15. Drugs in psychogeriatrics;393
23.1;Introduction;393
23.2;Pharmacokinetic and pharmacodynamic aspects of ageing;394
23.3;Other aspects of ageing of relevance to psychotropic drug therapy;395
23.4;Unwanted effects of psychotropic drugs—some general principles;398
23.5;Antidepressant drugs and the treatment of depression;399
23.6;Minor tranquillizers and the treatment of anxiety and insomnia;402
23.7;Major tranquillizers and the treatment of paranoid states;402
23.8;The drug treatment of organic brain syndrome;403
23.9;Lithium and the treatment of mania and recurrent depression;405
23.10;Non-psychotropic drugs causing psychiatric problems;406
23.11;Conclusions;407
23.12;References;407
24;Chapter 16. Other uses of psychotropic drugs in psychiatry;412
24.1;Anorexia nervosa;412
24.2;Obesity;415
24.3;Sexual disorders;416
24.4;Drugs to improve sexual performance;418
24.5;Other uses of hormones in psychiatry;419
24.6;References;420
25;Index of drug interactions;422
26;Index of international trade names;424
27;Subject index;436